9,789 Shares in Axon Enterprise, Inc (NASDAQ:AXON) Acquired by ASR Vermogensbeheer N.V.

Key Points

• ASR Vermogensbeheer N.V. acquired approximately 9,789 shares of Axon Enterprise, Inc. valued at around $5.148 million in the first quarter.
• Axon Enterprise reported a 32.6% year-over-year revenue increase with earnings per share (EPS) of $2.12, surpassing analyst expectations.
• Recent analyst ratings for Axon Enterprise indicate a positive outlook, with multiple firms raising their price targets, some up to $1,000, all maintaining a "buy" rating.

ASR Vermogensbeheer N.V. purchased a new stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 9,789 shares of the biotechnology company's stock, valued at approximately $5,148,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock valued at $4,540,005,000 after buying an additional 185,571 shares during the last quarter. Capital World Investors increased its stake in shares of Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after purchasing an additional 841,772 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Axon Enterprise by 58,725.5% during the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after purchasing an additional 763,431 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Axon Enterprise by 19.8% during the 4th quarter. Northern Trust Corp now owns 716,926 shares of the biotechnology company's stock worth $426,083,000 after purchasing an additional 118,469 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research note on Thursday, July 17th. JMP Securities upped their price target on shares of Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a research note on Tuesday, July 22nd. Northland Securities set a $800.00 price target on shares of Axon Enterprise in a research note on Tuesday, August 5th. Wolfe Research assumed coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They issued an "outperform" rating on the stock. Finally, Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the company an "overweight" rating in a research note on Friday, July 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $837.69.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 905 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total transaction of $702,632.95. Following the completion of the transaction, the president directly owned 268,735 shares in the company, valued at $208,643,166.65. This represents a 0.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Garnreiter sold 5,913 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the transaction, the director owned 17,740 shares of the company's stock, valued at approximately $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,585 shares of company stock worth $16,100,838 in the last 90 days. Corporate insiders own 5.70% of the company's stock.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock traded down $39.70 on Tuesday, reaching $778.99. 351,310 shares of the stock were exchanged, compared to its average volume of 706,657. The firm's 50 day moving average is $775.48 and its 200-day moving average is $666.90. Axon Enterprise, Inc has a one year low of $346.71 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm has a market cap of $61.15 billion, a PE ratio of 192.34, a P/E/G ratio of 30.92 and a beta of 1.36.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same quarter in the prior year, the firm posted $1.20 EPS. The firm's quarterly revenue was up 32.6% on a year-over-year basis. As a group, analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.